Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2017–2018

Takashita, Emi; Daniels, Rod S.; Fujisaki, Seiichiro; Gregory, Vicki; Gubareva, Larisa V.; Huang, Weiijuan; Hurt, Aeron C.; Lackenby, Angie; Nguyen, Ha; Pereyaslov, Dmitriy; Roe, Merryn; Samaan, Magdi; Subbarao, Kanta; Tse, Herman; Wang, Dayang; Yen, Hui‐Ling; Zhang, Wenqing; Meijer, Adam

doi:10.1016/j.antiviral.2020.104718

Cited by 103 publications

(80 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Evidence suggests that the detection of the PA I38T substitution can be considered a laboratory correlate of clinically relevant baloxavir resistance (Gubareva and Fry 2019). Because global surveillance of baloxavir resistance is essential, the World Health Organization (WHO) Global Influenza Surveillance and Response System (GISRS) Expert Working Group for Surveillance of Antiviral Susceptibility (WHO-AVWG) (https://www.who.int/influ enza/gisrs_laboratory/antiviral_susceptibility/ en/) has initiated a global analysis of circulating influenza viruses in the 2017-2018 influenza season (Takashita et al 2020). The monitoring of baloxavir susceptibility is important for public health planning purposes and for making clinical recommendations for antiviral use.…”

Section: Resultsmentioning

confidence: 99%

Influenza Polymerase Inhibitors: Mechanisms of Action and Resistance

Takashita

2020

Cold Spring Harb Perspect Med

Self Cite

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

Influenza Polymerase Inhibitors: Mechanisms of Action and Resistance

Takashita

2020

Cold Spring Harb Perspect Med

Self Cite

View full text Add to dashboard Cite

“…Decreased susceptibility to baloxavir has been reported in Japan, where utilization has been more common, [101][102][103][104][105] and surveillance for resistance among circulating influenza viruses is ongoing in Japan and the United States. [106][107][108] In contrast, high levels of resistance to amantadine and rimantadine persist among the influenza A viruses currently circulating. Adamantane medications are not recommended for use against influenza unless resistance patterns change.…”

Section: Antiviral Resistancementioning

confidence: 99%

Recommendations for Prevention and Control of Influenza in Children, 2020–2021

2020

Pediatrics

View full text Add to dashboard Cite

This statement updates the recommendations of the American Academy of Pediatrics for the routine use of influenza vaccine and antiviral medications in the prevention and treatment of influenza in children during the 2020-2021 season. The American Academy of Pediatrics (AAP) recommends routine influenza immunization of all children without medical contraindications, starting at 6 months of age. Influenza vaccination is an important intervention to protect vulnerable populations and reduce the burden of respiratory illnesses during the severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) pandemic. Any licensed, recommended, age-appropriate vaccine available can be administered, without preference for one product or formulation over another. Antiviral treatment of influenza with any licensed, recommended, ageappropriate influenza antiviral medication is recommended for children with suspected or confirmed influenza who are hospitalized, have severe or progressive disease, or have underlying conditions that increase their risk of complications of influenza. Antiviral treatment may be considered for any previously healthy, symptomatic outpatient not at high risk for influenza complications in whom an influenza diagnosis is confirmed or suspected, if treatment can be initiated within 48 hours of illness onset, and for children whose siblings or household contacts either are younger than 6 months or have a high-risk condition that predisposes them to complications of influenza. UPDATES FOR THE 2020-2021 INFLUENZA SEASON 1. The composition of the influenza vaccines for 2020-2021 has been updated. The recommended influenza A(H1N1)pdm09 and A(H3N2) components and the influenza B/Victoria component of the vaccine are new for this season. The B/Yamagata component is unchanged from the previous season. All quadrivalent influenza vaccines include these 4 components. The trivalent vaccines do not include influenza B/Yamagata.

show abstract

“…The total number and percentage of influenza positive cases were slightly higher (34 vs 33 %) compared to the previous 2017/2018 season, however, among the hospitalized patients, the difference was greater (34.7 vs 31.9 %). Only influenza A(H1N1)pdm09 and A(H3N2) viruses, at a ratio of 2 : 1, were identified in contrast to the previous season when type B viruses (mainly B/Yamagata-lineage) predominated accounting for 80 % of all influenza cases [32]. A similar proportion amongst circulating influenza viruses was observed in most European countries.…”

Section: Discussionmentioning

confidence: 73%

Genetic diversity of influenza A viruses circulating in Bulgaria during the 2018–2019 winter season

Korsun

Daniels

Angelova

et al. 2020

Journal of Medical Microbiology

View full text Add to dashboard Cite

Introduction. Influenza viruses evolve rapidly and change their antigenic characteristics, necessitating biannual updates of flu vaccines. Aim. The aim of this study was to characterize influenza viruses circulating in Bulgaria during the 2018/2019 season and to identify amino acid substitutions in them that might impact vaccine effectiveness. Methodology. Typing/subtyping of influenza viruses were performed using real-time Reverse Transcription-PCR (RT-PCR) and results of phylogenetic and amino acid sequence analyses of influenza strains are presented. Results. A(H1N1)pdm09 (66 %) predominated over A(H3N2) (34 %) viruses, with undetected circulation of B viruses in the 2018/2019 season. All A(H1N1)pdm09 viruses studied fell into the recently designated 6B.1A subclade with over 50 % falling in four subgroups: 6B.1A2, 6B.1A5, 6B.1A6 and 6B.1A7. Analysed A(H3N2) viruses belonged to subclades 3C.2a1b and 3C.2a2. Amino acid sequence analysis of 36 A(H1N1)pdm09 isolates revealed the presence of six–ten substitutions in haemagglutinin (HA), compared to the A/Michigan/45/2015 vaccine virus, three of which occurred in antigenic sites Sa and Cb, together with four–nine changes at positions in neuraminidase (NA), and a number of substitutions in internal proteins. HA1 D222N substitution, associated with increased virulence, was identified in two A(H1N1)pdm09 viruses. Despite the presence of several amino acid substitutions, A(H1N1)pdm09 viruses remained antigenically similar to the vaccine virus. The 28 A(H3N2) viruses characterized carried substitutions in HA, including some in antigenic sites A, B, C and E, in NA and internal protein sequences. Conclusion. The results of this study showed the genetic diversity of circulating influenza viruses and the need for continuous antigenic and molecular surveillance.

show abstract

Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2017–2018

Cited by 103 publications

References 21 publications

Influenza Polymerase Inhibitors: Mechanisms of Action and Resistance

Influenza Polymerase Inhibitors: Mechanisms of Action and Resistance

Recommendations for Prevention and Control of Influenza in Children, 2020–2021

Genetic diversity of influenza A viruses circulating in Bulgaria during the 2018–2019 winter season

Contact Info

Product

Resources

About